83 related articles for article (PubMed ID: 29291965)
21. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study.
Isla D; Felip E; Garrido P; Insa A; Majem M; Remon J; Trigo JM; de Castro J
Clin Transl Oncol; 2023 Jan; 25(1):283-291. PubMed ID: 36168085
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of tumor response after stereotactic body radiation therapy for lung cancer: Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
Alcantara P; Martínez BC; García-Esquinas MG; Belaústegui LG; Bustos A
J Clin Transl Res; 2020 Nov; 6(4):155-167. PubMed ID: 33501386
[TBL] [Abstract][Full Text] [Related]
23. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
Tan D; Gill S; Loh N
Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiotherapy in patients with lung tumors composed of mainly ground-glass opacity.
Onishi H; Shioyama Y; Matsumoto Y; Shibamoto Y; Miyakawa A; Suzuki G; Nishimura Y; Sasaki R; Miyawaki D; Kuriyama K; Komiyama T; Marino K; Aoki S; Saito R; Araya M; Maehata Y; Nonaka H; Tominaga L; Saito M; Sano N; Yamada S
J Radiat Res; 2020 May; 61(3):426-430. PubMed ID: 32219316
[TBL] [Abstract][Full Text] [Related]
25. Response evaluation after stereotactic ablative radiotherapy for localised non-small-cell lung cancer: an equipoise of available resource and accuracy.
Gouveia AG; Zalay OC; Chua KL; Moraes FY
Br J Radiol; 2020 Feb; 93(1106):20190647. PubMed ID: 31778312
[TBL] [Abstract][Full Text] [Related]
26. Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC.
Brooks ED; Verma V; Senan S; De Baere T; Lu S; Brunelli A; Chang JY;
J Thorac Oncol; 2020 Feb; 15(2):176-189. PubMed ID: 31712134
[TBL] [Abstract][Full Text] [Related]
27. Pathologic response after modern radiotherapy for non-small cell lung cancer.
Roy SF; Louie AV; Liberman M; Wong P; Bahig H
Transl Lung Cancer Res; 2019 Sep; 8(Suppl 2):S124-S134. PubMed ID: 31673516
[TBL] [Abstract][Full Text] [Related]
28. Early-Stage NSCLC: Advances in Thoracic Oncology 2018.
Osarogiagbon RU; Veronesi G; Fang W; Ekman S; Suda K; Aerts JG; Donington J
J Thorac Oncol; 2019 Jun; 14(6):968-978. PubMed ID: 30851441
[TBL] [Abstract][Full Text] [Related]
29. Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
Palma DA; Nguyen TK; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko B; Laba J; Kwan K; Gaede S; Lee T; Ward A; Warner A; Inculet R
JAMA Oncol; 2019 May; 5(5):681-688. PubMed ID: 30789648
[TBL] [Abstract][Full Text] [Related]
30. Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes.
Choi JI
Transl Lung Cancer Res; 2019 Feb; 8(1):32-47. PubMed ID: 30788233
[TBL] [Abstract][Full Text] [Related]
31. Feasibility of radiotherapy in nonagenarian patients: a retrospective study.
Kocik L; Geinitz H; Track C; Geier M; Nieder C
Strahlenther Onkol; 2019 Jan; 195(1):62-68. PubMed ID: 30167713
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directions.
Dunne EM; Fraser IM; Liu M
Ann Transl Med; 2018 Jul; 6(14):283. PubMed ID: 30105233
[TBL] [Abstract][Full Text] [Related]
33. Incidence of High-Risk Radiologic Features in Patients Without Local Recurrence After Stereotactic Ablative Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.
Ronden MI; van Sörnsen de Koste JR; Johnson C; Slotman BJ; Spoelstra FOB; Haasbeek CJA; Blom G; Bongers EM; Warner A; Ward A; Palma D; Senan S
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):115-121. PubMed ID: 29102278
[TBL] [Abstract][Full Text] [Related]
34. Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment.
Mattonen SA; Palma DA; Johnson C; Louie AV; Landis M; Rodrigues G; Chan I; Etemad-Rezai R; Yeung TP; Senan S; Ward AD
Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1121-8. PubMed ID: 26907916
[TBL] [Abstract][Full Text] [Related]
35. A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC).
Lee K; Le T; Hau E; Hanna GG; Gee H; Vinod S; Dammak S; Palma D; Ong A; Yeghiaian-Alvandi R; Buck J; Lim R
Int J Radiat Oncol Biol Phys; 2022 May; 113(1):40-59. PubMed ID: 34879247
[TBL] [Abstract][Full Text] [Related]
36. Undetected lymph node metastases in presumed early stage NSCLC SABR patients.
Cerra-Franco A; Diab K; Lautenschlaeger T
Expert Rev Anticancer Ther; 2016 Aug; 16(8):869-75. PubMed ID: 27279087
[TBL] [Abstract][Full Text] [Related]
37. Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study.
Nguyen TK; Senan S; Bradley JD; Franks K; Giuliani M; Guckenberger M; Landis M; Loo BW; Louie AV; Onishi H; Schmidt H; Timmerman R; Videtic GMM; Palma DA
Pract Radiat Oncol; 2018; 8(2):e71-e78. PubMed ID: 29291965
[TBL] [Abstract][Full Text] [Related]
38. Validation of High-Risk Computed Tomography Features for Detection of Local Recurrence After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.
Peulen H; Mantel F; Guckenberger M; Belderbos J; Werner-Wasik M; Hope A; Giuliani M; Grills I; Sonke JJ
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):134-41. PubMed ID: 27325481
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
